TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03883542

Intervention type: GENETIC
Intervention: genomic mutations study
Description: Sequencing of the DNA samples extracted from the subgroups~1. serous BOT tissue,~2. serous BOT tissue with non-invasive implants and~3. serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing~Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)

Intervention type: GENETIC
Intervention: genomic mutations study
Description: Sequencing of the DNA samples extracted from the subgroups~1. serous BOT tissue,~2. serous BOT tissue with non-invasive implants and~3. serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing~Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)

Intervention type: GENETIC
Intervention: genomic mutations study
Description: Sequencing of the DNA samples extracted from the subgroups~1. serous BOT tissue,~2. serous BOT tissue with non-invasive implants and~3. serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing~Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)
Study: NCT03361449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flamingo exercise
Description: Flamingo exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flamingo exercise
Description: Flamingo exercise
Study: NCT03883542

Intervention type: GENETIC
Intervention: genomic mutations study
Description: Sequencing of the DNA samples extracted from the subgroups~1. serous BOT tissue,~2. serous BOT tissue with non-invasive implants and~3. serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing~Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)
Study: NCT03361449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training with kinesthetic ability trainer
Description: training with kinesthetic ability trainer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training with kinesthetic ability trainer
Description: training with kinesthetic ability trainer
Study: NCT03889379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of albuterol
Description: Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
Study: NCT03181464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 4%
Description: lidocaine solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline .9% injection
Study: NCT01331824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles
Study: NCT02312336

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cohort A - Room temperature coronary perfusate
Description: Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cohort B - Cooled coronary perfusate
Description: Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).~The research intervention is the infusion of Hartmans solution cooled to 15 degrees.
Study: NCT03617653

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Group A
Description: Refer to detailed study Description

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Group A
Description: Refer to detailed study Description
Study: NCT00157014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Intravenous and Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Intravenous and Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Intravenous and Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Intravenous and Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral
Study: NCT00616733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-0777 tablets
Description: 0.1 mg, once-weekly, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-0777 tablets
Description: 0.3 mg, once-weekly or once every 2 weeks, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-0777 tablets
Description: 0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
Study: NCT01966627

Intervention type: OTHER
Intervention: ogtt
Description: oral glucose tolerance test

Intervention type: OTHER
Intervention: genotyping
Description: genotyping to look for risk alleles

Intervention type: OTHER
Intervention: abdominal and liver magnetic resonance imaging
Description: magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri

Intervention type: OTHER
Intervention: stool sample
Description: stool sample taken to investigate metabolites

Intervention type: OTHER
Intervention: liver biopsy
Description: liver biopsy to examine for cellular change and steatosis
Study: NCT00876447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 300U
Description: Botulinum toxin Type A 300U injections into the detrusor \> 12 weeks as needed for up to 3 years.
Study: NCT01151579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levalbuterol
Description: inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levalbuterol
Description: inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Nebulized albuterol 2.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Nebulized albuterol 2.5mg
Study: NCT00288860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone monitoring
Description: Three months of biweekly telephone monitoring and support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment-As-Usual
Description: Outpatient mental health Treatment As Usual (psychotherapy and/or medications)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-As-Usual
Description: Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
Study: NCT03442829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweet food consumption
Description: Sweet food consumption at breakfast

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-sweet food consumption
Description: Non-sweet food consumption at breakfast
Study: NCT00502801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doripenem
Description: 1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
Study: NCT02456649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MarginProbe
Description: Intraoperative MarginProbe use as adjunct to standard practice MarginProbe will be used on the lumpectomy specimen within 20 minutes of excision, prior to specimen Xray or gross pathology evaluation. This may take up to 5 minutes. MarginProbe will indicate a positive or negative reading for each of the 6 circumferential margins, and the results will be recorded. Any margins determined by to \< 5-10 mm by specimen Xray or gross pathology examination will be re-excised. In addition, any additional margins not already identified as \< 5-10 mm, but identified as positive by MarginProbe will be re-excised where feasible.
Study: NCT03282149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: IL-10 transgene DNA plasmid injected into the knee synovial capsule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: IL-10 transgene DNA plasmid injected into the knee synovial capsule
Study: NCT04619875

Intervention type: OTHER
Group type: OTHER
Intervention: KB5
Description: KB5, a novel glycan, is a Kaleido laboratory code for KB174

Intervention type: OTHER
Group type: OTHER
Intervention: SG1
Description: SG1 is a novel glycan

Intervention type: OTHER
Group type: OTHER
Intervention: Lactulose
Description: Lactulose is a synthetic dissacharide
Study: NCT03553433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Anti-psoriatic drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Indistinguishable tablets not containing apremilast, Placebo Oral Tablet
Study: NCT03641209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 10mg/mL infusion solution
Description: Intravenous paracetamol solution for infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half physiological saline solution as the non-active placebo solution
Study: NCT00547378

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
Study: NCT02097758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter device closure
Description: Closure of atrial septal defect with device~* choosing device size with 3D image and the formula~* we do not use sizing balloon for choosing of the device size
Study: NCT01260766

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oplon Active Patch
Description: Patches are placed over acne lesion overnight. Treatment is a single treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: same as active patch
Study: NCT03924791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: In combination with dexamethasone or methylprednisolone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Acetate
Description: In combination with lidocaine
Study: NCT02171104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion given on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion given on Day 0
Study: NCT03924791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: In combination with lidocaine
Study: NCT02171104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion given on Day 0
Study: NCT02045212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201
Description: SC injection twice a week during 13/26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection twice a week during 13/26 weeks
Study: NCT03284008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual manoeuver + stretching
Description: Patients in experimental group will receive, after AWS diagnose, a manual manoeuver to snap the cord, follow by a demonstration and education of the exercise to be made at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching exercise
Description: Patients in control group will receive, after AWS diagnose, just a demonstration and education of the exercise to be made at home.
Study: NCT02171104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion given on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion given on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion given on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion given on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMD Preparative Regimen
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMD Preparative Regimen
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMD Preparative Regimen
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMD Preparative Regimen
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMD Preparative Regimen
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteopetrosis Only Preparative Regimen
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Thiotepa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteopetrosis Haploidentical Only Preparative Regimen
Description: * Rituximab~* Alemtuzumab~* Busulfan~* Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cALD SR-A (Standard-Risk, Regimen A)
Description: N-acetylcysteine start day +1 through day +28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cALD SR-B (Standard-Risk, Regimen B)
Description: N-acetylcysteine start day +1through day +56
Study: NCT03282149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: IL-10 transgene DNA plasmid injected into the knee synovial capsule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: XT-150
Description: IL-10 transgene DNA plasmid injected into the knee synovial capsule
Study: NCT04407299

Intervention type: BEHAVIORAL
Intervention: self-administered structured questionnaire
Description: It was designed as a self-administered questionnaire with closed questions (yes/no questions, rating scale and multiple choice questions) and some open ended questions.

Intervention type: BEHAVIORAL
Intervention: self-administered structured questionnaire
Description: It was designed as a self-administered questionnaire with closed questions (yes/no questions, rating scale and multiple choice questions) and some open ended questions.
Study: NCT02336620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer acetate
Description: Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
Study: NCT03163849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir , daclatasvir
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral tablets
Study: NCT02744599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany
Description: Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
Study: NCT01546649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP-144-SR(6M)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP-144-SR(3M)
Study: NCT03708159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS + mindfulness meditation
Description: Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to active. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tDCS + mindfulness meditation
Description: Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to sham. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
Study: NCT02950142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPOE with order sets for lab testing
Description: CPOE including series of recommended tests ordered per indication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPOE without order sets for lab testing
Description: CPOE only
Study: NCT01393730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT01920542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: administration of dexmedetomidine on dexemedetomidine group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: no dexmedetomidine
Description: no administration of dexmedetomidine on control group
Study: NCT02790541

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyperbaric Oxygen Therapy
Description: 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
Study: NCT05064774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release technique
Description: myofascial release group took myofascial release (MFR) therapy sessions twice a week for 4 weeks between 4 and 7 weeks. MFR was applied to upper trapezius, SCM, pectoralis major-minor and sternocostal fascia. muscle was replaced elongated position and pressure was applied for 60-120 second.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: patients used sling up to 4 weeks. They did first 4 weeks passive/ assistive range of motion exercise. In 6-8 weeks they did active exercises. 8-12 weeks they did progressive resistive exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: patients used sling up to 4 weeks. They did first 4 weeks passive/ assistive range of motion exercise. In 6-8 weeks they did active exercises. 8-12 weeks they did progressive resistive exercises.
Study: NCT03123783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint (PD-1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint (PD-1) blocking antibody
Study: NCT03003260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBD chewing gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBD chewing gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04030520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POPPi behavioral intervention
Description: behavioral intervention with offer of HIV self test

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: POPPi behavioral intervention
Description: behavioral intervention
Study: NCT02984852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).
Study: NCT02171104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cALD HR-D (High-Risk, Regimen C)
Description: N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100